Latest Breaking News On - Unfit patients - Page 1 : comparemela.com

F Hoffmann-La Roche Ltd: Roche presents new data demonstrating the potential benefit of glofitamab and Lunsumio as fixed-duration, off-the-shelf treatment options for lymphoma

Data showcase the potential of glofitamab and Lunsumio to address diverse patient needsData presented at ASH 2022 and simultaneously published in the New England Journal of Medicine showed that glofitamab

United statesLevi garrawayMabthera rituxanGazyva gazyvaroSabine borngrGerard tobinBruno eschliVenclexta venclyxtoBirgit masjostLoren kalmNathalie altermattEuropean commissionDrug administrationHead of global product developmentAmerican society of hematologyRoche group

F Hoffmann-La Roche Ltd: Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs

Interim data from phase III HAVEN 7 study reinforce Hemlibra's efficacy and safety in infants with severe haemophilia A without factor VIII inhibitors1New and updated data support use of Polivy in diffuse

United statesPolatuzumab vedotinLevi garrawayMabthera rituxanGazyva gazyvaroSabine borngrGerard tobinBruno eschliBispecific cevostamabSileia urechVenclexta venclyxtoBirgit masjostLoren kalmKarsten kleineNathalie altermattEuropean commission

Investegate |F Hoffmann-La Roche Ltd Announcements | F Hoffmann-La Roche Ltd: Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs

Investegate announcements from F. Hoffmann-La Roche Ltd, Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs

United statesPolatuzumab vedotinBispecific cevostamabSileia urechLevi garrawayLoren kalmKarsten kleineNathalie altermattEuropean commissionDrug administrationHead of global product developmentAmerican society of hematologyRoche groupEuropean medicines agencyAmerican societyAnnual meeting

Phase 3 GLOW: first-line ibrutinib plus venetoclax improves outcomes in elderly or unfit CLL

Phase 3 GLOW: first-line ibrutinib plus venetoclax improves outcomes in elderly or unfit CLL
physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomTalha munir leedsObinutuzumab clbAmerican society of hematologyAmerican society of hematology annual meetingAmerican societyTalha munirLeeds teaching hospitalsProspective dataMinimal residual diseaseFixed duration ibrutinib plus venetoclaxVersus chlorambucil plus obinutuzumabFirst line treatmentUnfit patientsHematology annual

Johnson & Johnson : New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrated Deeper and Sustained Undetectable Minimal Residual Disease Outcomes in First-Line Chronic Lymphocytic Leukemia

Updated results from the MRD cohort of the Phase 2 CAPTIVATE study also highlight potential for treatment-free remissions with IMBRUVICA® plus venetoclax in an oral presentation at ASH. | December 11, 2021

United statesCraig tendlerObinutuzumab clbBernadette kingJessica mooreChristie corbettJanssen biotech incAmerican society of hematology annual meetingEuropean hematology associationJanssen research developmentJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonAmerican society of hematologyAmerican society of clinical oncology annual meetingVirtual congressGlobal head of late development